繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Dr. Reddy's Laboratories' Atomoxetine Hydrochloride Capsules Suspended in China

2024-09-03 22:06

10:06 AM EDT, 09/03/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) said in a regulatory filing Tuesday that China's National Medical Products Administration has issued an order suspending the import, sale, and use of the company's atomoxetine hydrochloride capsules, effective Aug. 30, for failing to meet the country's good manufacturing practice standards.

China's National Drug Joint Procurement Office has also issued an order to put the company on a "violation list", Dr. Reddy's said, adding the move suspends its eligibility to participate in drug procurement activities in the country starting Aug. 30 until Feb. 28, 2026.

Dr. Reddy's said it's in the process of determining the financial impact of the orders.

The company's shares were falling 2% in recent trading.

Price: 81.80, Change: -1.67, Percent Change: -2.00

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。